Working to Eradicate Gynecologic Cancers

Roberto Angioli, MD

Full Professor of Obstetrics and Gynecology
University Campus Bio-Medico of Rome
Via Alvaro del Portillo n. 200
Rome Italy 00128

Papers:
274 Predicting overall survival in patients with ovarian cancer: a new clinical model 356 Neratinib, an irreversible pan-ErbB receptor inhibitor, is highly effective against primary cervical cancer cell lines harboring HER2/neu gene mutations